61 related articles for article (PubMed ID: 21098902)
1. Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.
Wallerand H; Robert G; Bernhard JC; Ravaud A; Patard JJ
Arch Esp Urol; 2010 Nov; 63(9):773-87. PubMed ID: 21098902
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA
Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981
[TBL] [Abstract][Full Text] [Related]
3. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
4. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
Dorai T; Gehani N; Katz A
Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Fay JR; Steele VE; Lubet RA; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):657-66. PubMed ID: 8824370
[TBL] [Abstract][Full Text] [Related]
8. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
9. 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
Buchdunger E; Mett H; Trinks U; Regenass U; Müller M; Meyer T; Beilstein P; Wirz B; Schneider P; Traxler P
Clin Cancer Res; 1995 Aug; 1(8):813-21. PubMed ID: 9816050
[TBL] [Abstract][Full Text] [Related]
10. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
11. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.
Sion-Vardy N; Vardy D; Rodeck U; Kari C; Levin RM; Malkowicz SB
J Surg Res; 1995 Dec; 59(6):675-80. PubMed ID: 8538164
[TBL] [Abstract][Full Text] [Related]
14. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
15. Parallel contractile signal transduction pathways activated by receptors for thrombin and epidermal growth factor-urogastrone in guinea pig gastric smooth muscle: blockade by inhibitors of mitogen-activated protein kinase-kinase and phosphatidyl inositol 3'-kinase.
Zheng XL; Renaux B; Hollenberg MD
J Pharmacol Exp Ther; 1998 Apr; 285(1):325-34. PubMed ID: 9536028
[TBL] [Abstract][Full Text] [Related]
16. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
[TBL] [Abstract][Full Text] [Related]
18. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
Dinney CP; Parker C; Dong Z; Fan D; Eve BY; Bucana C; Radinsky R
Clin Cancer Res; 1997 Feb; 3(2):161-8. PubMed ID: 9815668
[TBL] [Abstract][Full Text] [Related]
19. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
20. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H; Schmidt LJ; Tindall DJ
Cancer Res; 2001 Oct; 61(20):7408-12. PubMed ID: 11606371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
